CellCentric

Ownership

Private

Modalities

Small molecule

CellCentric General Information

Inobrodib (CCS1477), a first-in-class oral p300/CBP inhibitor, is in Phase II clinical trials, showing promise particularly in multiple myeloma patients. Trials are active in the UK, US, and EU.[1][2][3]

Contact Information

Website

Primary Industry

Biotech

Corporate Office

Cambridge,
UK

Drug Pipeline

No pipeline data available

For full access to CellCentric's pipeline data

Book a demo

Key Partnerships

Takeda Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CellCentric Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view CellCentric's complete valuation and funding history, request access »